Bacteria DNA Genomics Protein 
XTalks
FEBRUARY 11, 2021
The Human Genome Project recently marked 20 years since the publication of the first full sets of human genomic sequences, an endeavor that spanned well over a decade. Today, new next-generation sequencing technologies allow for the sequencing of complex genomes within just a day or two.
Pharmaceutical Technology
FEBRUARY 15, 2023
Within the emerging innovation stage, cell therapy for ocular disorders, coronavirus vaccine components, and DNA polymerase compositions are disruptive technologies that are in the early stages of application and should be tracked closely. CRISPR nucleases serve as an important genome editing tool.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Drug Discovery World
JULY 30, 2024
RK: Much of current drug discovery has focused on the proteome (the ‘druggable genome’, which represents 1.5% of the human genome). The transcriptome, unlike static DNA sequences, is a dynamic and complex target in drug discovery, reflecting real-time changes in gene expression across different conditions and tissues.
Drug Discovery World
FEBRUARY 6, 2024
Sanofi has stated that it intends to become the first pharma company “powered by AI at scale”, and as part of this ambition, agreed a collaboration with BioMap to co-develop advanced AI models and protein Large Language Models that that it hopes will enable biologics design and multiparametric optimisation 2. Obulytix is not alone.
XTalks
DECEMBER 24, 2020
From isolating SARS-CoV-2 in early January to sequencing its genome shortly thereafter and having a prototype vaccine against it within days, scientific process and progress have held steadfast throughout the pandemic. Most antibody drugs and vaccines have been developed to target parts of the spike protein. Innovations.
pharmaphorum
SEPTEMBER 14, 2020
Here he gives us a deeper look at how genomic medicine is evolving and the barriers that are preventing it from reaching its full potential. I saw this, in particular, with the finishing of the human genome,” says Charlie. “At In reality, finishing the human genome was the first step of what is a long journey.”.
The Pharma Data
OCTOBER 19, 2020
By leveraging the comprehensive genomic, transcriptomic and proteomic profiling available through the Caris Molecular Intelligence® platform, physicians from Winship will be able to further prioritize therapeutic options and determine which clinical trial opportunities may benefit their patients.
Expert insights. Personalized for you.
119 
Let's personalize your content